Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy
Go back to Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy| Pfizer Inc. (NYSE: PFE) | Delayed: 25.21 -0.71 (2.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.92 | 52 Week High | $37.39 | |||
| Open | $25.58 | 52 Week Low | $28.25 | |||
| Day High | $25.36 | P/E | 15.28 | |||
| Day Low | $24.94 | EPS | $1.65 | |||
| Volume | 119,614,341 | |||||
| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $9.91 | |||
| Open | $0.18 | 52 Week Low | $3.10 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.18 | EPS | $-0.48 | |||
| Volume | 1,155,576 | |||||
